Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma.

Baekelandt BM, Hjermstad MJ, Nordby T, Fagerland MW, Kure EH, Heiberg T, Buanes T, Labori KJ.

HPB (Oxford). 2016 Mar;18(3):247-54. doi: 10.1016/j.hpb.2015.09.004. Epub 2015 Nov 19.

2.

Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma.

Sandhu V, Bowitz Lothe IM, Labori KJ, Skrede ML, Hamfjord J, Dalsgaard AM, Buanes T, Dube G, Kale MM, Sawant S, Kulkarni-Kale U, Børresen-Dale AL, Lingjærde OC, Kure EH.

Mol Oncol. 2016 Feb;10(2):303-16. doi: 10.1016/j.molonc.2015.10.011. Epub 2015 Nov 3.

PMID:
26590090
3.

Tumour exosome integrins determine organotropic metastasis.

Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D.

Nature. 2015 Nov 19;527(7578):329-35. doi: 10.1038/nature15756. Epub 2015 Oct 28.

4.

Serum N-Glycome Characterization in Patients with Resectable Periampullary Adenocarcinoma.

Hamfjord J, Saldova R, Stöckmann H, Sandhu V, Bowitz Lothe IM, Buanes T, Lingjærde OC, Labori KJ, Rudd PM, Kure EH.

J Proteome Res. 2015 Dec 4;14(12):5144-56. doi: 10.1021/acs.jproteome.5b00395. Epub 2015 Nov 17.

PMID:
26515733
5.

AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.

Kjersem JB, Thomsen M, Guren T, Hamfjord J, Carlsson G, Gustavsson B, Ikdahl T, Indrebø G, Pfeiffer P, Lingjærde O, Tveit KM, Wettergren Y, Kure EH.

Pharmacogenomics J. 2016 Jun;16(3):272-9. doi: 10.1038/tpj.2015.54. Epub 2015 Aug 11.

PMID:
26261061
6.

Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.

Labori KJ, Katz MH, Tzeng CW, Bjørnbeth BA, Cvancarova M, Edwin B, Kure EH, Eide TJ, Dueland S, Buanes T, Gladhaug IP.

Acta Oncol. 2016 Mar;55(3):265-77. doi: 10.3109/0284186X.2015.1068445. Epub 2015 Jul 25.

PMID:
26213211
7.

Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver.

Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen TM, García-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe IM, Kure EH, Hernandez J, Doussot A, Ebbesen SH, Grandgenett PM, Hollingsworth MA, Jain M, Mallya K, Batra SK, Jarnagin WR, Schwartz RE, Matei I, Peinado H, Stanger BZ, Bromberg J, Lyden D.

Nat Cell Biol. 2015 Jun;17(6):816-26. doi: 10.1038/ncb3169. Epub 2015 May 18.

PMID:
25985394
8.

High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence.

Andersen V, Vogel LK, Kopp TI, Sæbø M, Nonboe AW, Hamfjord J, Kure EH, Vogel U.

PLoS One. 2015 Mar 20;10(3):e0119255. doi: 10.1371/journal.pone.0119255. eCollection 2015.

9.

Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas.

Sandhu V, Bowitz Lothe IM, Labori KJ, Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, Børresen-Dale AL, Ikdahl T, Kure EH.

Mol Oncol. 2015 Apr;9(4):758-71. doi: 10.1016/j.molonc.2014.12.002. Epub 2014 Dec 19.

10.

Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis.

Vogel LK, Sæbø M, Høyer H, Kopp TI, Vogel U, Godiksen S, Frenzel FB, Hamfjord J, Bowitz-Lothe IM, Johnson E, Kure EH, Andersen V.

PLoS One. 2014 Aug 28;9(8):e105254. doi: 10.1371/journal.pone.0105254. eCollection 2014.

11.

Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines.

Wennerström AB, Lothe IM, Sandhu V, Kure EH, Myklebost O, Munthe E.

PLoS One. 2014 Aug 22;9(8):e103873. doi: 10.1371/journal.pone.0103873. eCollection 2014.

12.

FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.

Kjersem JB, Skovlund E, Ikdahl T, Guren T, Kersten C, Dalsgaard AM, Yilmaz MK, Fokstuen T, Tveit KM, Kure EH.

BMC Cancer. 2014 May 19;14:340. doi: 10.1186/1471-2407-14-340.

13.

Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.

Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM.

PLoS One. 2014 Feb 3;9(2):e87746. doi: 10.1371/journal.pone.0087746. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e98836.

14.

Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.

Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH.

Mol Oncol. 2014 Feb;8(1):59-67. doi: 10.1016/j.molonc.2013.09.001. Epub 2013 Sep 21.

15.

Molecular responses to toxicological stressors: profiling microRNAs in wild Atlantic salmon (Salmo salar) exposed to acidic aluminum-rich water.

Kure EH, Sæbø M, Stangeland AM, Hamfjord J, Hytterød S, Heggenes J, Lydersen E.

Aquat Toxicol. 2013 Aug 15;138-139:98-104. doi: 10.1016/j.aquatox.2013.04.004. Epub 2013 Apr 24.

16.

Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.

Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH.

BMC Cancer. 2012 Nov 20;12:534. doi: 10.1186/1471-2407-12-534.

17.

KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem.

Kure EH, Hamfjord J, Stangeland AM, Tveit KM, Ikdahl T.

Expert Rev Mol Diagn. 2012 May;12(4):327-8. doi: 10.1586/erm.12.29. No abstract available.

PMID:
22616697
18.

Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing.

Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, Kure EH.

PLoS One. 2012;7(4):e34150. doi: 10.1371/journal.pone.0034150. Epub 2012 Apr 17.

19.

Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations.

Hamfjord J, Stangeland AM, Skrede ML, Tveit KM, Ikdahl T, Kure EH.

Diagn Mol Pathol. 2011 Sep;20(3):158-65. doi: 10.1097/PDM.0b013e31820b49e2.

PMID:
21817902
20.

ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues.

Marcos NT, Bennett EP, Gomes J, Magalhaes A, Gomes C, David L, Dar I, Jeanneau C, DeFrees S, Krustrup D, Vogel LK, Kure EH, Burchell J, Taylor-Papadimitriou J, Clausen H, Mandel U, Reis CA.

Front Biosci (Elite Ed). 2011 Jun 1;3:1443-55.

PMID:
21622148
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk